Roche Highlights Encouraging Long-Term Data in Hematological Disorders at ASH 2024
核心洞察
Roche will present over 40 abstracts at ASH 2024, showcasing advancements in lymphoma treatment with Polivy, Lunsumio, and Columvi, demonstrating its commitment to improving patient outcomes.
Five-year data from the POLARIX study shows Polivy, combined with R-CHP, has a positive trend in overall survival for first-line diffuse large B-cell lymphoma (搜索) (DLBCL) patients.
Extended follow-up data from studies on Lunsumio and Columvi indicate long-lasting remissions and immune system recovery, supporting their use as fixed-duration bispecific antibodies for lymphoma.
Roche is set to present more than 40 abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego, USA. The data highlights Roche's ongoing efforts to improve patient outcomes in various blood disorders, with a focus on lymphoma treatments. Key presentations will feature long-term follow-up data for approved medicines like Polivy (polatuzumab vedotin), Lunsumio (mosunetuzumab), and Columvi (glofitamab), as well as new investigational combination data.
Polivy: Five-Year Data from POLARIX Study
Five-year data from the phase III POLARIX study (abstract #469) reinforces the potential of Polivy in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) to provide durable and lasting remissions. The data, for the first time, shows a positive trend in overall survival (OS) for people with first-line diffuse large B-cell lymphoma (搜索) (DLBCL). This is a significant advancement in an area that has seen limited progress in nearly two decades.
Lunsumio and Columvi: Extended Follow-Up Data
Extended follow-up data of up to four years from the pivotal GO29781 study of Lunsumio (abstract #4407) and NP30179 study of Columvi (abstract #865) demonstrate long-lasting remissions and immune system recovery after the end of treatment. These findings support the use of fixed-duration bispecific antibodies for third-line or later (3L+) follicular lymphoma (搜索) (FL) and DLBCL, respectively.
Subcutaneous Formulation of Lunsumio
The first presentation of data for a subcutaneous formulation of Lunsumio monotherapy from the pivotal phase II GO29781 study (abstract #1645) shows high rates of deep and durable responses and low rates and severity of cytokine release syndrome in people with 3L+ FL. Subcutaneously administered Lunsumio could further improve the patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy.
STARGLO Study: Patient-Reported Outcomes
New patient-reported outcomes data from the phase III STARGLO study (abstract #5132) indicate comparable health-related quality of life between treatment arms, despite a higher median number of cycles received with the Columvi combination (11 versus 4). Together with the significant improvement in OS observed in the study, these data support the potential benefit for patients with second-line or later DLBCL.
Investigational Combinations
New and updated data from investigational study combinations of Polivy with bispecific antibodies Lunsumio and Columvi in relapsed or refractory DLBCL, including the phase Ib/II NP39488 (abstract #988) and phase II GO40516 (abstract #989) studies, add to the growing body of evidence demonstrating the potential of novel bispecific antibody/Polivy combinations in earlier treatment lines, and support their ongoing phase III development.